Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 975-983

  Jetter, Alexander ^a,b   Fätkenheuer, Gerd ^b   Frank, Dorothee ^b   Klaassen, Tobias ^b   Seeringer, Angela ^c   Doroshyenko, Oxana ^b   Kirchheiner, Julia ^c   Hein, Wolfgang ^b   Schömig, Edgar ^b   Fuhr, Uwe ^b   Wyen, Christoph ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DEXTROMETHORPHAN; DEXTRORPHAN; DIGOXIN; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; HUSTENSTILLER RATIOPHARM; LOPINAVIR PLUS RITONAVIR; MIDAZOLAM MALEATE; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; MALE; MOLECULAR PROBE; MORNING DOSAGE; PHENOTYPE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DEXTROMETHORPHAN; DIGOXIN; DOWN-REGULATION; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDAZOLAM; MIDDLE AGED; P-GLYCOPROTEIN; PYRIMIDINONES; RITONAVIR; YOUNG ADULT;

EID: 78651069086     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1648     Document Type: Article

References (44)

1. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 2009; 85:434-438.
2. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008; 36:205-216. (Pubitemid 351185732)
3. Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 2007; 35:1687-1693.
4. Morgan ET. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 2001; 29:207-212.
5. Chang KC, Lauer BA, Bell TD, Chai H. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; 311:1132-1133. (Pubitemid 8356442)
6. Carcillo JA, Doughty L, Kofos D, et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med 2003; 29:980-984. (Pubitemid 36783172)
7. Frye RF, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 2002; 8:315-319.
8. Slaviero KA, Clarke SJ, Rivory LP. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol 2003; 4:224-232.
9. O'Neil WM, Gilfix BM, DiGirolamo A, Tsoukas CM, Wainer IW. N-acetylation among HIV-positive patients and patients with AIDS: when is fast, fast and slow, slow? Clin Pharmacol Ther 1997; 62:261-271. (Pubitemid 27417791)
10. O'Neil WM, Gilfix BM, Markoglou N, Di Girolamo A, Tsoukas CM, Wainer IW. Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome. Eur J Clin Pharmacol 2000; 56:231-240.
11. O'Neil WM, Drobitch RK, MacArthur RD, et al. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics 2000; 10:171-182.
12. O'Neil WM, Pezzullo JC, Di Girolamo A, Tsoukas CM, Wainer IW. Glucuronidation and sulphation of paracetamol in HIV-positive patients and patients with AIDS. Br J Clin Pharmacol 1999; 48:811-818.
13. Wyen C, Fuhr U, Frank D, et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008; 84:75-82.
14. Tomalik-Scharte D, Jetter A, Kinzig-Schippers M, et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 2005; 33:1859-1866.
15. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41:67-76.
16. Chen M, Ma L, Drusano GL, Bertino JS, Jr., Nafziger AN. Sex differences in CYP3A activity using intravenous and oral midazolam. Clin Pharmacol Ther 2006; 80:531-538.
17. He P, Court MH, Greenblatt DJ, Von Moltke LL. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 2005; 77:373-387.
18. Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 2003; 13:595-606. (Pubitemid 37311146)
19. Bebia Z, Buch SC, Wilson JW, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther 2004; 76:618-627.
20. Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 2002; 12:375-383.
21. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics? Clin Pharmacokinet 2002; 41:329-342
22. Larsen UL, Hyldahl Olesen L, Guldborg Nyvold C, et al. Human intestinal P-glycoprotein activity estimated by the model substrate digoxin. Scand J Clin Lab Invest 2007; 67:123-134.
23. Becker Y. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers - a review and hypothesis. Virus Genes 2004; 28:5-18.
24. Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21:1431-1438. (Pubitemid 26066634)
25. + T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77:11708-11717.
26. + T cell depletion and viral replication in SIV infection. Science 1998; 280:427-431.
27. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the 'cocktail' approach. Clin Pharmacol Ther 2007; 81:270-283.
28. Kurnik D, Wood AJ, Wilkinson GR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther 2006; 80:228-234. (Pubitemid 44301092)
29. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002; 72:718-728.
30. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM, Jr., Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998; 64:133-143.
31. Tomalik-Scharte D, Doroshyenko O, Kirchheiner J, et al. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur J Clin Pharmacol 2008; 64:1033-1035.
32. Borges S, Li L, Hamman MA, Jones DR, Hall SD, Gorski JC. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos 2005; 33:1052-1055.
33. Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007; 63:321-333.
34. Hu OY, Tang HS, Lane HY, Chang WH, Hu TM. Novel single-point plasma or saliva dextromethorphan method for determining CYP2D6 activity. J Pharmacol Exp Ther 1998; 285:955-960.
35. Yeh GC, Tao PL, Ho HO, Lee YJ, Chen JY, Sheu MT. Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. J Biomed Sci 2003; 10:552-564.
36. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104:147-153.
37. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97:3473-3478.
38. Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004; 76:73-84.
39. Jones AE, Brown KC, Werner RE, et al. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur J Clin Pharmacol 2010; 66:475-485.
40. Hariparsad N, Nallani SC, Sane RS, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44:1273-1281.
41. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72:1-9. (Pubitemid 34833182)
42. Edwards P, Wodak A, Cooper DA, Thompson IL, Penny R. The gastrointestinal manifestations of AIDS. Aust N Z J Med 1990; 20:141-148.
43. Dickinson L, Khoo S, Back D. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008; 3:296-305.
44. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet 2005; 44:1035-1050.